कृपया अन्य खोज का प्रयास करें
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jeremy Max Levin | 70 | 2014 | President, CEO & Chairman |
Amit Rakhit | 54 | 2019 | Member of Scientific & Clinical Advisory Board |
Barbara G. Duncan | 59 | 2017 | Independent Director |
Karen Bernstein | 71 | 2015 | Independent Director |
Bart Friedman | 79 | 2015 | Lead Independent Director |
Kevin Joseph Fitzgerald | 55 | 2021 | Independent Director |
Robert Michael Poole | 66 | 2021 | Independent Director |
Jacqueline A. French | - | 2017 | Member of Scientific & Clinical Advisory Board |
Alexander Kolevzon | - | 2020 | Member of Scientific & Clinical Advisory Board |
Joy A. Cavagnaro | - | 2021 | Member of the Scientific & Clinical Advisory Board |
Robert S. Langer | 75 | 2021 | Chairman of the Scientific & Clinical Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है